{"id":"70acb78e-1d14-54f6-bd7d-6310d8055889","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-benefit-tracks-pik3ca","predicate":"increases","statement":"Among 964 colorectal cancer patients, regular aspirin use after diagnosis was associated with superior colorectal-cancer-specific survival in those with mutated-PIK3CA cancers, multivariate hazard ratio for cancer-related death 0.18 with 95% confidence interval 0.06 to 0.61, and superior overall survival at hazard ratio 0.54, whereas among patients with wild-type PIK3CA there was no association with cancer-specific survival at hazard ratio 0.96 or overall survival at 0.94, with the interaction between aspirin and PIK3CA yielding a p value of 0.009.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"0bd45012-6bd7-5be9-93ea-2f3edf8ec608","mechanism_event_label":"Aspirin after diagnosis tracked with much better survival, but only in tumours carrying one particular mutation.","subject":{"id":"8ac405bf-3ea0-539a-8e5e-abf503dc7081","slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"},"object":{"id":"6aa1fd38-b08d-5d63-b6e5-4abe9626a7a6","slug":"colorectal-cancer-survival","display_name":"Colorectal-cancer-specific survival","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0bd45012-6bd7-5be9-93ea-2f3edf8ec608","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-benefit-tracks-pik3ca-event","event_type":"observed_intervention","label":"Aspirin after diagnosis tracked with much better survival, but only in tumours carrying one particular mutation.","description":"Among 964 colorectal cancer patients, regular aspirin use after diagnosis was associated with superior colorectal-cancer-specific survival in those with mutated-PIK3CA cancers, multivariate hazard ratio for cancer-related death 0.18 with 95% confidence interval 0.06 to 0.61, and superior overall survival at hazard ratio 0.54, whereas among patients with wild-type PIK3CA there was no association with cancer-specific survival at hazard ratio 0.96 or overall survival at 0.94, with the interaction between aspirin and PIK3CA yielding a p value of 0.009.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"1fdad3b9-0e1b-57cf-ac32-a32d7a91eb76","slug":"pik3ca","display_name":"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha / PIK3CA","entity_type_key":"gene"},"role":"stratifying_gene","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"14ee1715-a2a1-53f6-9b85-47bef559bc66","slug":"pik3ca-mutant-tumour","display_name":"Colorectal cancer carrying a PIK3CA mutation","entity_type_key":"cellular_process"},"role":"benefiting_group","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c8a31ed4-f2ca-5d43-8352-e9935129a785","slug":"ptgs2","display_name":"Cyclooxygenase-2 (PTGS2)","entity_type_key":"protein"},"role":"proposed_mediator","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"8ac405bf-3ea0-539a-8e5e-abf503dc7081","slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"6aa1fd38-b08d-5d63-b6e5-4abe9626a7a6","slug":"colorectal-cancer-survival","display_name":"Colorectal-cancer-specific survival","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/aspirin-research/23094721.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43\", \"start_char\": 0, \"end_char\": 2456, \"text_sha256\": \"0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Molecular pathological epidemiology in 964 colorectal cancer patients from the Nurses’ Health Study and the Health Professionals Follow-up Study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Regular aspirin use after diagnosis, stratified by tumour PIK3CA mutation status","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Observational cohorts with tumour genotyping, not a randomised trial, so aspirin use after diagnosis is chosen rather than assigned and may travel with other differences between patients.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.","comparator":null,"unit":null,"notes":"","entity":{"slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Aspirin after diagnosis tracked with much better survival, but only in tumours carrying one particular mutation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[asa-p23094721] Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. (2012). https://pubmed.ncbi.nlm.nih.gov/23094721/ DOI: 10.1056/nejmoa1207756","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Colorectal tumour","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"5d48bef0-c66c-56be-bc4f-fcf04b473f18","evidence_kind":"source_excerpt","locator":"Lines 598-609","start_line":598,"end_line":609,"excerpt":"### asa-benefit-tracks-pik3ca\nAmong 964 colorectal cancer patients, regular aspirin use after diagnosis was associated with superior colorectal-cancer-specific survival in those with mutated-PIK3CA cancers, multivariate hazard ratio for cancer-related death 0.18 with 95% confidence interval 0.06 to 0.61, and superior overall survival at hazard ratio 0.54, whereas among patients with wild-type PIK3CA there was no association with cancer-specific survival at hazard ratio 0.96 or overall survival at 0.94, with the interaction between aspirin and PIK3CA yielding a p value of 0.009.\nCondition category: biomarker_context\nnutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.\nplain_language: Aspirin after diagnosis tracked with much better survival, but only in tumours carrying one particular mutation.\norganism: Human\ntissue_or_cell_type: Colorectal tumour\nexperimental_model: Molecular pathological epidemiology in 964 colorectal cancer patients from the Nurses’ Health Study and the Health Professionals Follow-up Study\nlimitations: Observational cohorts with tumour genotyping, not a randomised trial, so aspirin use after diagnosis is chosen rather than assigned and may travel with other differences between patients.\nexposure: Regular aspirin use after diagnosis, stratified by tumour PIK3CA mutation status\nevidence_span: {\"source_cache\": \"artifacts/aspirin-research/23094721.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43\", \"start_char\": 0, \"end_char\": 2456, \"text_sha256\": \"0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43\"}\n[asa-p23094721] Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. (2012). https://pubmed.ncbi.nlm.nih.gov/23094721/ DOI: 10.1056/nejmoa1207756","model_system":"Molecular pathological epidemiology in 964 colorectal cancer patients from the Nurses’ Health Study and the Health Professionals Follow-up Study","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [asa-p23094721] Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. (2012). https://pubmed.ncbi.nlm.nih.gov/23094721/ DOI: 10.1056/nejmoa1207756","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"712cf519-cd27-5a8b-9e2f-961a98d7a27e","stable_key":"import-f8641d02-8413-5bd8-92e9-62ad49286e81","title":"Aspirin: the serine it acetylates, the enzyme that acetylation creates, the dose that separates platelet from vessel wall, and the metabolite that is a different drug (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"93dd4343051c131e40d4fc3c95a978cd65478c13dcdb3f2d42507c49b09cb647","revision_id":"694e8ee7-49ca-5e6c-b58b-8ba8f82c2ad8","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}